Natalizumab-associated progressive multifocal leukoencephalopathy [3]

New England Journal of Medicine

Volumn 367, Issue 9, 2012, Pages 871-872

  Cervera, Carlos ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB; VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; JC VIRUS; LETTER; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT DURATION; VIRUS REPLICATION; BLOOD; CHEMICALLY INDUCED DISORDER; FEMALE; IMMUNOLOGY; MALE; MULTIPLE SCLEROSIS; NOTE; ASTROCYTE; HUMORAL IMMUNITY; OLIGODENDROGLIA; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84865483379     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1207116     Document Type: Letter

References (4)

1. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
2. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:1067-74.
3. Reid CE, Li H, Sur G, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011;204:237-44.
4. Planas R, Jelčić I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012;42:790-8.